Differential Inhibitory Effects of A.ntidiabetic Drugs on Arterial Smooth Muscle Cell Proliferation
We compared three drugs representing different classes of antidiabetic pharmacology (glyburide, a sulfonylurea; pioglitazone, a thiazolidinedione; and metformin, a biguanide) in terms cf their direct effects on proliferation of cultured arterial smooth muscle cells (SMC).
Rat aortic SMC were seeded at 4 x 10'135 mm well. After 24 h, they were treated every 2 to 4 days for 2 weeks with 5% fetal bovine serum (FBS) in normal culture medium containing either drug vehicles or a low and a high but nuntoxic level of glyburide (0.5 and 2.5 *mol/L), pioglitazone (1 and 5 PmollL), and metfonnin (20 and 100 pmol/L). Vehicletreated cells increased from 2 I II to 6 2 1 to 42 t 3 to 210 2 14 (cells per well x IO'; 5 wells each) from day zero to 4 to 9 to 14. From day 9 to 14 these cell numben were decreased an average of 20% by the 2.5 pmol/L glyburide (P < .05) and 43% by the 5 ~mol/L pioglitazone (P < .05). The low levels of giybucide and pioglitazone and both the low and high levels of metfonnin failed to influence cell numbers.
In a second experiment, 
METHODS
Thoracic aortae from Dahl S rats were stripped of adwntitia and cut into multiple ring segments. These rings were cultured as explants in a series of two plastic wells per ring (each ring remaining 1 week in each well) according to a previously described methodology.' Mixtures of endotlrelial and smooth muscle cell outgrowths from rings in the first set of wells were discarded.
Smooth muscle cell outgrowth from rings in the second set of wells (with no endothelinl cells) were grown to confluence and subcultured through 4 to 5 patsages to tibtain enough for later study. These smooth muscle cells were stored under liquid nitrogen and used as needed for ercperimentation.
Cells were characterized in their sixth passage as smooth muscle and not endothelia! cells by their morphology and immunofluorescent staining.' The), were also examined for acute cytotoxic effects of glyburide, pioglitlzone, and metformin at multiple concentrations of each drug. Then they were seeded at 4 s IO'/ 35 mm well (seventh passage) and af!e: l day treated every 2 to 4 days with Ssi, fetal bovine serum (FBS; Gibco, Grand Island, NY) ,'triatment) at :he end of which crl! *:iabi!ity (via trypan blue extrusion) was examined again.
In the first of two gro:*:th experiments, noni:*,ic con centrations of al! three antidiabetic drugs (0.5 and 2.5 pmol i L glyburide, 1 and 5 p-rrol! L pioglitazone, 20 and 1100 lmol/ L metformin) 'xere ek,unined in parallel for effects on cell proliferation.
The trig" level of each drug closely approximams ievcis rerortcd previoosit to be not only maximally effective in terms of various activities in vitro in vascular and nonvascular preparations"." but also nontoxic in vitro'.',r" and comparable to plasma levels found after oral administration of hypoglycemic doses.",",.' In a second experiment, only glyburide (2.0 pnoI/L) and pioglitzzone (2.5 umol/ L) were tes!ed. each in the presence as well as in the absence of a high Ievel of human insulin f 10 mU I mL) added to tl,e growth medium in separate wells. The baseline level of bovine insulin in this medium (calculated from the FBS hormone profile provided by Gibco) was negligible by comparison: fKilO3 mU /mL in this experimezt and fl.UB@l mr;/mL in experiment 1, In both experiments, cell numbers were expressed as mean + SE and, aiter han.;formation to achicvehomogeneity oi variance (if new sary), they were eva!uated b:: analysis of variance f ANOVA) foliowed by several mmtiple mean comparison p:ocedures to identify cignificant individual mean differe.lces at P < .0X
RESULTS
In the first growth experiment, the medium contaming 5% FBS and onlc drug vehicles increased control cell nunitcr~ rrom 1 z 0 on da\ zero to 6 2 1 on day 4 to 42 z 3 on da; Y to 21: = '14 on day 14 <per WC;; x 10'; 5 wells each). None of the drugs at the low levels used in this experiment (0.5 pmol,' L glyburide, 1 pmol i L pioglitazone, 20 pmol i L mctformm) affected cell growth. However, at the ligh drug levels both plyburide (2.5 ;rmol/'L) and pioglitazone (5 pmol, L) inhibited proliferative growth of t!Tese aortic smooth muscles celis (17 < .F3). The high level of metformin (100 hrmot / L) slightl! thw+ not significantly enhanced proliicra!i:-e growth oi these cells by an average of Y';; from .la!s 9 to 14. T!w average inhibitors action of the high le:-el of pioglita/.onc was at least twice as great (-43% I as that of !!w high :e!-ei of glyburide (-X%) o:er the same period i;' < .C3). Thus, bY the end of the *.hpcriment !dav 14; control cells = 210 = 14 per WC Y IC' I cellj treated with the high level of vioglitazo,w ndmbrred only 139 z 6 per well (xl@'), cells tre;.ted with the hiRh level of Rlvburide numbered 162 + 5 per well (x10') and c%ls treated with the high level of metformin numbered slightly more than control (2.19 + 7 per well X10'). In addition, dye exclusion tests with trypan blue indicated no differential effects of these antidinbetic agents on cell viability on day 14. This agreed with our initial acute tests for cytotoxlcity which were positive only at levels 5 to 10 times higher than the high levels employed in this long term experiment.
In the second growth experiment ( Figure  1 ) we found that even half the high ievel of pio,qlitarone used in ewpenment 1 (2.5 gmol /i) arrested nearly all rapid proliferative growth of these Dahl S aortic smooth muscle cells in response to growth medium containing a ?ew ba!ch of FBS. A level of glyburide similar to the high level used in experiment i (2.0 pmol/L) only partially attenuated such gro\:th. In this second experiment, a high level oi insulin add4 to the medium in separate wells slightly but significantly stimulated cell proliferation. Two-factor AN-OVA revealed no statistically meaningful interaction between the insulin and the drugs in this experiment. In other words, !he large and differential inhibitory effects of these drugs on cell proliferation were not significantly influenced by the high insulin atid the small stimulator) effect of this high insulin was not significantly influenced by the drugs (although pioglitazone tended to iniubit it). As in experiment 1, there were no effects of drugs :c: m..~: slllnj on cell vidbility at the conclusion of this experiment.
DISCUSSION
There are at least two important findings from the presxt study.
Firs:, antidiabetic drugs may differ markedly in tr.eir ability to inhibit proliferation of arterial smooth muscle cells in culture. Our results indicate that the thiazolidincdione pioglitazone inhibits the rapid proliferation characteristic of smooth muscle cells derived from rat aortic explants to a much gleater extent than the sulfonylurea glyburide and certainly the biguanide metformin.
Second, this inhibitory action of pioglitazone and even the lesser inhibitory action of glyburide do not appear to significantly afiect the ability of insulin to stimulate pro%xation of these cells. Nor does insulin affect the inhibitory actions of the drugs.
Our work cwfirms a previous demonstration by Dubey et al'of the antiproliferative potential of pioglitazone in rat arterial smooth nwscle cells grown in medium containing 5% ietal calf serum. However, we were unable to confirm the antiproliferative effect of metformin previously reported by Biinting et aL3 The reasons for this may be threefold.
First, the arterial smccth muscle cells employed by Bi;nting et al' were described as human in origin (although no particular vessel or method of primary culture was specified). Our cells were rat in origin obtained spc'ritizally from aorta by the explant method. Second, the growth serum employed by Biinting et al was derived from diabetic and nondiabetic patien!s.'They reported that the antiproliferative action of metformin was independent of the sewn?
Nonetheless, because the serum we employed (fetal bovine serum) is not human serum, cur effects of metfcrmin may be different for that r~ascn. Finally, we did not test metformin at levels above 100 flmol/L.
Biinting et al3 only reported notable antiproliferotive activity of metformin zt much higher levels (1,000 to 40,000 pmcl/ L). H.>w-ever, !hey also reported cell death at high levels of metfcrmin." Therefore, had we raised metformin above IOU Ir.mol/ L we might have seen a significant antiprolifcrative rffect as well but possibly related to an undesirable, nonspecific toxic action. Whether metfcrmin can exert a potentially beneficial antiproliferative effect by way of a nontoxic mechanism remains to be mere fully explored.
Mechanisms responsible for the inhibitory effects of glyburide and pioglitazcne on proliferation of the Dahl S aortic smooth muscle cells in the present study also remain to be determined.
This study suggests that these two different agents do not inhibit proliferation of this particular cell line by interacting with the abilitv of insulir. iti vti-nulate proliferation.
They 
